{
  "docId": "019dd923-5ca1-7489-b639-45501f4b359b",
  "docSlug": "158df8627a0b9aca",
  "documentTitle": "Opioid Conflicts Majority Staff Report",
  "authorId": "McKinsey",
  "authorName": "U.S. House Committee on Oversight and Reform",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "portrait",
  "aspectRatio": 0.773,
  "pageNumber": 17,
  "pageCount": 53,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "appendix_disclosure",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Contains extensive footnotes documenting specific internal McKinsey engagement lists and correspondence.",
  "elementsJson": [
    "paragraph",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b639-45501f4b359b/17",
  "deckHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b639-45501f4b359b#slide-17",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "All of the 37 FDA contracts for which McKinsey provided staffing information to the Committee were staffed by at least one McKinsey consultant who also consulted for Purdue.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49b-648d261d1dc9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Contract Value: $1,799,534",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-cdec-74db-b49b-689f0f461b72",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "All of the 37 FDA contracts for which McKinsey provided staffing information to the Committee were staffed by at least one McKinsey consultant who also consulted for Purdue.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a87a4ffd-d80e-405d-835c-19ee845b5f3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.15,
        "y": 0.4
      },
      "kind": "paragraph",
      "text": "The first OSE contract, worth $1,799,534, charged McKinsey with developing a new concept of operations for the Office. The contract was staffed by nine McKinsey consultants. Four of the nine consultants on the contract were also consulting for Purdue during this time, including partner Jeff Smith. A fifth McKinsey consultant working on this OSE project, Navjot Singh, had previously participated on Purdue matters, and documents suggest he may have been participating on Purdue and private sector clients on FDA-related issues during this time.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d93ec824-682d-403f-b22b-cb5d5d8a51a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.15,
        "y": 0.31
      },
      "kind": "paragraph",
      "text": "CDER's Office of Surveillance and Epidemiology (OSE) evaluates the safety profiles of drugs available to American consumers, maintaining a system of post-marketing surveillance programs to identify adverse events that did not appear during the drug development process. McKinsey undertook two contracts related to drug safety at OSE between 2011 and 2012.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e1a36cc6-6657-4928-9e57-29a7e6c7e20b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.15,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "The Committee has identified four illustrative categories of FDA contracts that raise particular conflict of interest concerns.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "edca3003-935a-4ce7-9326-ea2e89cb00fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.7,
        "x": 0.15,
        "y": 0.56
      },
      "kind": "source-note",
      "text": "66-70: Detailed references to McKinsey engagement lists and Committee correspondence.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "51c73ffe-0260-47d3-b550-397a3ef8a9e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.15,
        "y": 0.11
      },
      "kind": "title",
      "text": "3. McKinsey's FDA Contracts Overlapped with McKinsey's Work for Opioid Manufacturers, Creating Significant Conflicts of Interest",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fee02f93-62c1-47ec-a059-5615cd7fd4fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.7,
        "x": 0.15,
        "y": 0.28
      },
      "kind": "title",
      "text": "i. FDA Office of Surveillance and Epidemiology Contracts (2011-2012)",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63710d83-d394-4743-ae1c-525598f16b90",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Contract Value",
      "numberRaw": "$1,799,534",
      "numberKind": "money",
      "actionTitle": "McKinsey's FDA Contracts Overlapped with McKinsey's Work for Opioid Manufacturers, Creating Significant Conflicts of Interest",
      "calloutText": "All of the 37 FDA contracts for which McKinsey provided staffing information to the Committee were staffed by at least one McKinsey consultant who also consulted for Purdue.",
      "numberScale": null,
      "numberValue": 1.799,
      "metricFamily": "other",
      "numberCurrency": "$"
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 28,
      "from": 6,
      "beatId": "ca9c3ab4-903c-4ff0-b53d-42335d2ce596",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents extensive evidence of McKinsey's conflicts of interest, including consultant overlaps and contract details.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 53,
      "from": 1,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "ee9686db-f8b5-4bc9-bf6e-2d29966ee033",
      "evidence": "The document implies the cost of inaction through its presentation of McKinsey's conflicts of interest and their potential impact on the opioid epidemic.",
      "position": 0,
      "objective": "What is the cost of inaction in addressing McKinsey's conflicts of interest?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}